In the offering, the Boca Raton, Fla.-based company plans to offer 2.2 million shares of its common stock at a price of $6.80 per share, bringing in approximately $15 million in gross proceeds.
The offering also includes a 30-day underwriter’s option to purchase an additional 330,882 shares for the same price, which could pull in approximately $2.3 million extra for the company, before underwriting discounts and other expenses. The offering is expected to close on September 17.
Sensus said it plans to use net proceeds for general corporate purposes including R&D, expansion of product lines and roll-out of new products, according to a press release.
Last month, Sensus Healthcare said that it won FDA 510(k) clearance for its SRT-100+ next-gen superficial radiation therapy system.